Cargando…

Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis

Uveitis is a severe autoimmune disease, and a common cause of blindness; however, its individual cellular dynamics and pathogenic mechanism remain poorly understood. Herein, by performing single-cell RNA sequencing (scRNA-seq) on experimental autoimmune uveitis (EAU), we identify disease-associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, He, Xie, Lihui, Zhu, Lei, Li, Zhaohuai, Wang, Rong, Liu, Xiuxing, Huang, Zhaohao, Chen, Binyao, Gao, Yuehan, Wei, Lai, He, Chang, Ju, Rong, Liu, Yizhi, Liu, Xialin, Zheng, Yingfeng, Su, Wenru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532430/
https://www.ncbi.nlm.nih.gov/pubmed/36195600
http://dx.doi.org/10.1038/s41467-022-33502-7
_version_ 1784802114740944896
author Li, He
Xie, Lihui
Zhu, Lei
Li, Zhaohuai
Wang, Rong
Liu, Xiuxing
Huang, Zhaohao
Chen, Binyao
Gao, Yuehan
Wei, Lai
He, Chang
Ju, Rong
Liu, Yizhi
Liu, Xialin
Zheng, Yingfeng
Su, Wenru
author_facet Li, He
Xie, Lihui
Zhu, Lei
Li, Zhaohuai
Wang, Rong
Liu, Xiuxing
Huang, Zhaohao
Chen, Binyao
Gao, Yuehan
Wei, Lai
He, Chang
Ju, Rong
Liu, Yizhi
Liu, Xialin
Zheng, Yingfeng
Su, Wenru
author_sort Li, He
collection PubMed
description Uveitis is a severe autoimmune disease, and a common cause of blindness; however, its individual cellular dynamics and pathogenic mechanism remain poorly understood. Herein, by performing single-cell RNA sequencing (scRNA-seq) on experimental autoimmune uveitis (EAU), we identify disease-associated alterations in cell composition and transcriptional regulation as the disease progressed, as well as a disease-related molecule, PIM1. Inhibiting PIM1 reduces the Th17 cell proportion and increases the Treg cell proportion, likely due to regulation of PIM1 to the protein kinase B (AKT)/Forkhead box O1 (FOXO1) pathway. Moreover, inhibiting PIM1 reduces Th17 cell pathogenicity and reduces plasma cell differentiation. Importantly, the upregulation of PIM1 in CD4(+) T cells and plasma cells is conserved in a human uveitis, Vogt-Koyanagi-Harada disease (VKH), and inhibition of PIM1 reduces CD4(+) T and B cell expansion. Collectively, a dynamic immune cellular atlas during uveitis is developed and implicate that PIM1 may be a potential therapeutic target for VKH.
format Online
Article
Text
id pubmed-9532430
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95324302022-10-06 Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis Li, He Xie, Lihui Zhu, Lei Li, Zhaohuai Wang, Rong Liu, Xiuxing Huang, Zhaohao Chen, Binyao Gao, Yuehan Wei, Lai He, Chang Ju, Rong Liu, Yizhi Liu, Xialin Zheng, Yingfeng Su, Wenru Nat Commun Article Uveitis is a severe autoimmune disease, and a common cause of blindness; however, its individual cellular dynamics and pathogenic mechanism remain poorly understood. Herein, by performing single-cell RNA sequencing (scRNA-seq) on experimental autoimmune uveitis (EAU), we identify disease-associated alterations in cell composition and transcriptional regulation as the disease progressed, as well as a disease-related molecule, PIM1. Inhibiting PIM1 reduces the Th17 cell proportion and increases the Treg cell proportion, likely due to regulation of PIM1 to the protein kinase B (AKT)/Forkhead box O1 (FOXO1) pathway. Moreover, inhibiting PIM1 reduces Th17 cell pathogenicity and reduces plasma cell differentiation. Importantly, the upregulation of PIM1 in CD4(+) T cells and plasma cells is conserved in a human uveitis, Vogt-Koyanagi-Harada disease (VKH), and inhibition of PIM1 reduces CD4(+) T and B cell expansion. Collectively, a dynamic immune cellular atlas during uveitis is developed and implicate that PIM1 may be a potential therapeutic target for VKH. Nature Publishing Group UK 2022-10-04 /pmc/articles/PMC9532430/ /pubmed/36195600 http://dx.doi.org/10.1038/s41467-022-33502-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Li, He
Xie, Lihui
Zhu, Lei
Li, Zhaohuai
Wang, Rong
Liu, Xiuxing
Huang, Zhaohao
Chen, Binyao
Gao, Yuehan
Wei, Lai
He, Chang
Ju, Rong
Liu, Yizhi
Liu, Xialin
Zheng, Yingfeng
Su, Wenru
Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis
title Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis
title_full Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis
title_fullStr Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis
title_full_unstemmed Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis
title_short Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis
title_sort multicellular immune dynamics implicate pim1 as a potential therapeutic target for uveitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532430/
https://www.ncbi.nlm.nih.gov/pubmed/36195600
http://dx.doi.org/10.1038/s41467-022-33502-7
work_keys_str_mv AT lihe multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT xielihui multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT zhulei multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT lizhaohuai multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT wangrong multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT liuxiuxing multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT huangzhaohao multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT chenbinyao multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT gaoyuehan multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT weilai multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT hechang multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT jurong multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT liuyizhi multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT liuxialin multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT zhengyingfeng multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis
AT suwenru multicellularimmunedynamicsimplicatepim1asapotentialtherapeutictargetforuveitis